Menorrhagia, Dysmenorrhea
Conditions
Keywords
Mirena, Heavy Menstrual Bleeding, Dysmenorrhea, Japan, Post-marketing surveillance
Brief summary
The primary objective in this study is collecting post-marketing information on the safety. Thus, it includes information under the routine clinical practice on adverse events (AEs) and adverse drug reactions (ADRs) including expulsion and abnormal bleeding that occur within the first 12 months Mirena insertion. The secondary objective(s) in this study is/are collecting information on Mirena effectiveness, such as periodic blood loss and Quality of life (QOL), use of analgesic and dysmenorrhea pain as far as these are recorded under routine clinical practice.
Detailed description
This local, non-interventional, multicenter, single-cohort study using primary data includes patients treated with Mirena for Heavy menstrual bleeding(HMB) and/or dysmenorrhea (contraception is not included). A total of 600 patients (valid for safety analysis) is planned to be enrolled in two years. No formal sample size estimation was conducted, it was determined based on feasibility. Target population is patients with HMB and/or dysmenorrhea diagnosis. The treatment should be performed based on the product label in Japan. The standard observation period will last for 12 months from starting Mirena treatment.
Interventions
The treatment of Mirena should comply with the local product information.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Female patients diagnosed with HMB or/and dysmenorrhea. * Patients for whom newly starting treatment with Mirena was made as per investigator's routine treatment practice * Written informed consent
Exclusion criteria
* Patient whose purpose is only contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-emergent adverse events (TEAEs) | Up to 12 months |
| Number of participants with adverse drug reaction | Up to 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in Quality of Life parameters assessed using MMAS or MDQ score after 3 and 12 months | Baseline and 3 months, Baseline and 12 months | MMAS: Menorrhagia Multi Attribute Score for Heavy Menstrual Bleeding and MDQ: Menstrual Distress Questionnaire for dysmenorrhea |
| Change from baseline in bleeding characterized by Pictorial Blood loss Assessment Chart (PBAC) score to 12 months | Baseline and 12 months | — |
| Change from baseline in use of analgesics after Mirena insertion | Baseline and 12 months | — |
| Change from baseline in dysmenorrhea pain using Visual Analogue scale | Baseline and 1 month, Baseline and 3 months, Baseline and 6 months, Baseline and 12 months | — |
| Change from baseline in monthly bleeding intensities (the number of spotting and/or bleeding days) to 12 months | Baseline and 12 months | — |
Countries
Japan
Outcome results
None listed